Ofer Lider
12Patents
7h-index
14Co-inventors
59Inventor score
Filing activity: Nov 19, 1992 → Jan 4, 2006
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US5474987A | Methods of using low molecular weight heparins treatment of pathological processes | Human Necessities | 43 | Expired |
| US5352667A | Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them | Human Necessities | 39 | Expired |
| US5519005A | Method of inhibition of cellular and molecular level biological interactions utilizing non-peptidic surrogates of the Arg-Gly-Asp sequence | Human Necessities | 16 | Expired |
| US6020323A | Compositions and methods for regulation of active TNF-.alpha. | Emerging Cross-Sectional Technologies | 15 | Expired |
| US6906170B1 | Anti-inflammatory peptides derived from IL-2 and analogues thereof | Human Necessities | 10 | Expired |
| US5908837A | Methods of using low molecular weight heparins for prevention or treatment of pathological processes | Human Necessities | 9 | Expired |
| US5686431A | Methods of using low molecular weight heparins for treatment of pathological processes | Human Necessities | 7 | Expired |
| US5861382A | Methods for regulation of active TNF-.alpha. | Emerging Cross-Sectional Technologies | 5 | Expired |
| US6750207B1 | Compositions for the regulation of cytokine activity | Chemistry; Metallurgy | 2 | Expired |
| US7285536B2 | Anti-cancer therapeutic compounds | Human Necessities | 1 | Expired |
| US8691772B2 | HSP60, HSP60 peptides and T cell vaccines for immunomodulation | Chemistry; Metallurgy | 1 | Active |
| US7332480B2 | Compositions for the regulation of cytokine activity | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.